Determination of carbapenem resistance mechanism in clinical isolates of Pseudomonas aeruginosa isolated from burn patients, in Tehran, Iran

Akbar Mirsalehian; Davood Kalantar-Neyestanaki; Morovat Taherikalani; Fereshteh Jabalameli; Mohammad Emaneini

doi:10.1016/j.jegh.2017.04.002

<Previous Article In Issue

Download article (PDF)

Next Article In Issue>

Volume 7, Issue 3, September 2017, Pages 155 - 159

Determination of carbapenem resistance mechanism in clinical isolates of Pseudomonas aeruginosa isolated from burn patients, in Tehran, Iran

Authors

Akbar Mirsalehian^a, Davood Kalantar-Neyestanaki^b, Morovat Taherikalani^c, Fereshteh Jabalameli^a, Mohammad Emaneini^a^{, *}^,emaneini@tums.ac.ir

^aDepartment of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

^bStudent Research Committee, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

^cDepartment of Microbiology, School of Medicine, Lorestan University of Medical Sciences, Lorestan, Iran

^*Corresponding author at: Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, 100 Poursina St., Keshavarz Blvd., Tehran, Iran.

Corresponding Author

Mohammad Emaneiniemaneini@tums.ac.ir

Received 24 January 2016, Revised 12 March 2017, Accepted 22 April 2017, Available Online 29 April 2017.

DOI: 10.1016/j.jegh.2017.04.002 How to use a DOI?
Keywords: Pseudomonas aeruginosa; Carbapenem-resistant; Carbapenemase; AmpC; oprD
Abstract: Carbapenems are the most important therapeutic options that effect against serious infections caused by multidrug resistant Pseudomonas aeruginosa (MDR-PA) isolates. Carbapenems resistant isolates of P. aeruginosa are increasing worldwide. The aim of this study was to determine the carbapenem resistance mechanisms in clinical P. aeruginosa isolates from burn patients, in Tehran, Iran. A total of 53 non-duplicated isolates of carbapenem-resistant P. aeruginosa were collected from burn patients. The presence of carbapenemase genes were determined by PCR. AmpC overproducer isolates were detected by phenotypic method. The mutation and transcription level of oprD were determined by PCR-sequencing and quantitative Real-time PCR (RT-PCR), respectively. Twenty-seven (50.9%) isolates were positive for carbapenemase (bla_VIM = 25 and bla_IMP = 2) and showed high-level resistance to imipenem and meropenem. Twenty-eight isolates were AmpC overproducers. All isolates had a mutation in the oprD gene and down-regulation of oprD was found in 56.6% of MDR-PA isolates. Although the presence of carbapenemase is the common mechanism of resistant to carbapenem, but carbapenem resistance was found by oprD mutation-driven and the AmpC overproducing isolates in Tehran, Iran.
Copyright: © 2017 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd.
Open Access: This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Pseudomonas aeruginosa is one of the most important causes of nosocomial infections especially in patients with secondary infection associated with burns and cystic fibrosis [1]. Infections caused by multidrug-resistant P. aeruginosa (MDR-PA) can be fatal for involved patients [2]. Carbapenems are among the last-line antibiotics for infections caused by MDR-PA [3]. Carbapenem-resistant isolates are gradually increasing worldwide and in Iran [2,3]. The mechanisms of resistance to carbapenems are multifactorial, including production of carbapenemase such as metallo beta-lactamase (MBLs), AmpC overproducer, mutation in oprD gene and over-expression of efflux-pumps [3,4]. MBLs are important groups of β-lactamases, which can hydrolyze carbapenems and extended spectrum cephalosporins [5,6]. AmpC β-lactamases are weakly able to hydrolysis the carbapenems and usually, are expressed constitutively at a low level in P. aeruginosa [6,7]. Mutations in ampC locus may lead to overexpression of AmpC β-lactamases in P. aeruginosa isolates and cause resistance to carbapenems [2,6]. Porin proteins in outer membranes such as OprD is a channel for entrance of amino acids and carbapenems especially imipenem in P. aeruginosa [1,2]. Therefore, lose of OprD or reduced OprD protein expression could cause a resistance to imipenem in P. aeruginosa [1,2]. Active efflux or overexpression of efflux-pumps is a responsible mechanism for moving antibacterial agents such as antibiotics from inside to outside of the cell. The aim of this study was to determine the carbapenem resistance mechanisms in carbapenem-resistant isolates of P. aeruginosa collected from burn patients, in Tehran, Iran.

2. Materials and methods

2.1. Bacterial isolates

Totally, fifty-three non-duplicated carbapenem resistant P. aeruginosa were collected from 130 burn patients who were admitted to Shahid Motahari Hospital during June 2011 to March 2012 in Tehran, Iran. Bacterial identification was performed by standard biochemical tests [8] such as Gram staining, colony morphology, non-lactose fermentation on MacConkey agar, oxidase and catalase tests, Triple Sugar Iron agar (TSI) and oxidative-fermentative (OF) test.

2.2. Antimicrobial susceptibility testing

Antimicrobial susceptibility patterns of isolates were determined using the disk diffusion method according to the Clinical and Laboratory Standards [9]. The following antibiotics (MAST, UK) were tested: Imipenem (IMI: 10 µg), meropenem (MEM: 10 µg), aztreonam (ATM: 30 µg), carbenicillin (CB: 30 µg), amikacin (AK: 10 µg), gentamicin (GM: 10 µg), ciprofloxacin (CIP: 5 µg), cefepime (CPM: 30 µg), ceftazidime (CAZ: 30 µg) and polymyxin B (PB: 300unit). The minimum inhibitory concentrations (MICs) of IMI and MEM (Jaber Ebne Hayyan Pharmaceutical Co. Iran) were determined by the microbroth dilution method. Susceptibility breakpoints were defined according to CLSI recommendations [9]. Escherichia coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as quality control strains in antimicrobial susceptibility testing and MICs.

2.3. AmpC overproducer isolates

Isolates were considered as AmpC overproducers when there was at least a twofold dilution difference between each one of the followings: MICs of IMI or MEM, MICs of IMI or MEM plus 250 µg cloxacillin (Sigma-Aldrich, Product Number: 27555) [10].

2.4. DNA extraction and amplification of carbapenemas genes

The genomic DNA from isolates was prepared using genomic DNA extraction kit (tip 100; Bioneer, Korea) according to the manufacturer’s instructions. Detection of bla_VIM, bla_IMP, bla_SMP, bla_SIM, bla_GIM, bla_NDM, bla_AIM, bla_KPC, bla_OXA-48, and bla_GES was done by PCR as described previously [3,11]. P. aeruginosa strain psa1 (GenBank accession No. KT313641.1) and P. aeruginosa strain PAFSHIRAN (GenBank accession No. JX644173.1) were used as the positive control for bla_VIM and bla_IMP [12].

2.5. PCR amplification and sequencing of the oprD gene

PCR amplification and sequencing of oprD were performed using primers listed in Table 1. PCR conditions were as follows: 95 °C for 5 min and 30 cycles of 95 °C for 45 s, 61 °C for 45 s, and 72 °C for 2 min. A final extension step was performed at 72 °C for 10 min. Sequences of both strands of the amplicons were determined at Macrogen (Seoul, South Korea) and were compared with P. aeruginosa PAO1 as a reference strain (GenBank accession No. CAA78448) (http://www.ncbi.nih.gov/BLAST).

Primer name	Primer sequence (5′-3′)	Amplicon size (bp)	Reference	Use
oprD	F-CGCCGACAAGAAGAACTAGC R-GTCGATTACAGGATCGACAG	1413	[10]	Amplification and Sequencing of oprD
	F-TCGATGCCTTCGGCTACCT F-GCGCTTGATCACCCGGAATG F-GGTAGCCGTATACACCTCCG		This study	Used for sequencing of IS elements in oprD
	F-TCCGCAGGTAGCACTCAGTTC R-AAGCCGGATTCATAGGTGGTG	191	[13]	Used for quantitative RT-PCR
rpsL	F-GCAACTATCAACCAGCTGGTG R-GCTGTGCTCTTGCAGGTTGTG	230	[14]	Used for quantitative RT-PCR

Table 1

Primers used in this study.

2.6. RNA extraction and quantitative reverse transcription PCR (quantitative RT-PCR)

The quantitative RT-PCR was applied for determination the transcription level of oprD gene in carbapenem resistant isolates except in those with oprD gene disruption by insertion sequence (IS elements), according to sequencing results . Briefly, strains were grown in LB broth by using shaker incubator at 37 °C and 180 rpm to the late log phase (optical density at 600 nm [OD 600] = 0.8–1) and collected by centrifugation at 10,000 RPM in 5 min. Total RNA was extracted with Hybrid-R^TM (GeneALL, Cat. No. 305-101), according to the manufacturer’s recommendations and then RNase-Free DNase I (Thermo Scientific™) was used for elimination of DNA contaminations. Concentrations and quality of RNA were determined by spectrophotometer (NanoDrop 2000; Thermo Scientific). Reverse transcription (cDNA synthesize) was performed by the 2-step RT-PCR kit (Vivantis Co, Malaysia), according to the manufacturer’s recommendations. The transcription level of the oprD gene was determined by relative quantitative RT-PCR as described using the standard curve method and using the RealQ Plus 2x Master Mix Green Kit (Ampliqon, Danmark) in Line-Gene K Thermal Cycler FDQ-48A BIOER (Hangzhou Bioer Technology Co., Ltd, China). Expression of the 30S ribosomal gene rpsL was assessed in parallel to normalized transcriptional levels of target gene. Decreased expression of oprD genes was considered as relevant if expression of oprD was ≤30%, in compared with that of P. aeruginosa PAO1 [15]. The quantitative RT-PCR of oprD and rpsL was performed using primers listed in Table 1.

2.7. Statistical analysis

Statistical analysis of data was carried out using the SPSS 16 statistical software. We used the χ² and T-test analysis for comparison of data. A difference was considered statistically significant at P-value of ≤0.05.

3. Results

Among 53 P. aeruginosa isolates, 71.6% (38/53) were from males and 28.4% (15/53) from females. All isolates were recovered from wounds of burns’ patients. All isolates were resistant to imipenem, meropenem, aztreonam, carbenicillin, amikacin, gentamicin, ciprofloxacin and cefepime. Twenty-six percent (14/53) of isolates were susceptible to ceftazidime and all isolates were susceptible to polymyxin B. All carbapenem resistant isolates showed a high-level resistance to carbapenems. The range of MIC to IMI and MEM were 16–512 µg/ml and 4–128 µg/ml, respectively (Table 2 ). Fifty-two percent (28/53) of isolates were AmpC overproducers and AmpC overproduction caused an increase in the MICs of imipenem, but not meropenem (Table 2). The PCR assay of all carbapenem resistant isolates revealed that 47.1% (25/53) and 3.7% (2/53) of isolates were positive for bla_VIM and bla_IMP, respectively and all isolates were negative for bla_OXA-48, bla_KPC, bla_GES, bla_GIM, bla_AIM, bla_SPM, bla_NDM and bla_SIM genes. All isolates had a mutation in the oprD gene and down-regulation of oprD was found in 56.6% of the carbapenem resistant isolates of P. aeruginosa. In 67.9% (36/53) of the isolates, oprD was defective by deletion mutations (by 1-98 bp deletion) and these deletion mutations were occurred in upstream of the oprD gene. The oprD gene in 26.4% (14/53) of carbapenem-resistant P. aeruginosa isolates was disrupted by ISPpu21 insertion sequence (KM053284.1: GenBank accession number for ISPpu21) and in one isolate oprD was disrupted by ISPpu22 insertion sequence (KJ825703.1: GenBank accession number for ISPpu22). No carbapenemase genes were detected in isolates for which oprD was disrupted by insertion sequence. One isolate had a premature stop codon by single point mutation and in one isolate oprD was not detectable by PCR (Table 3 ). The distribution of antibiotic resistance, level of MICs to imipenem and meropenem, carbapenemase genes and AmpC overproducer isolates in P. aeruginosa isolates with oprD mutation have been summarized in Table 2. Eighty percent (30/38) of carbapenem-resistants had a relevant decrease in oprD expression (≤30%) compared with that of the reference PAO1 strain. Expression of oprD could not be determined in isolates that oprD was disrupted by IS elements (n = 15).

Susceptibility patterns									MIC^* (µg/ml)				AmpC	bla_VIM	bla_IMP	Mutations in oprD	No of isolates

IMI^¥	MEM	ATM	CB	AK	GM	CIP	CPM	CAZ	IMI	IMI/COL	MEM	MEM/COL
R^#	R	R	R	R	R	R	R	S	16	4	16	16	+	–	–	ISPpu21	3
R	R	R	R	R	R	R	R	S	16	4	32	16	+	–	–	ISPpu21	1
R	R	R	R	R	R	R	R	S	16	4	32	32	+	–	–	ISPpu21	1
R	R	R	R	R	R	R	R	S	16	8	16	16	–	–	–	ISPpu21	1
R	R	R	R	R	R	R	R	R	16	16	8	8	–	–	–	98n Deletion	1
R	R	R	R	R	R	R	R	S	32	2	32	32	+	–	–	ISPpu21	1
R	R	R	R	R	R	R	R	S	32	8	16	16	+	–	+	23n Deletion	1
R	R	R	R	R	R	R	R	S	32	8	32	16	+	–	–	ISPpu21	1
R	R	R	R	R	R	R	R	S	32	8	32	32	+	–	+	75n Deletion	1
R	R	R	R	R	R	R	R	S	32	8	32	32	+	–	–	ISPpu21	1
R	R	R	R	R	R	R	R	R	32	8	32	32	+	–	–	ISPpu21	2
R	R	R	R	R	R	R	R	R	32	16	4	4	–	+	–	3n Deletion	1
R	R	R	R	R	R	R	R	R	32	16	8	8	–	–	–	15 n Deletion	1
R	R	R	R	R	R	R	R	R	32	16	16	16	–	+	–	13n Deletion	1
R	R	R	R	R	R	R	R	R	32	16	16	16	–	+	–	16n Deletion	1
R	R	R	R	R	R	R	R	R	32	16	64	64	–	–	–	7n Deletion	1
R	R	R	R	R	R	R	R	R	64	8	8	8	+	–	–	ISPpu21	1
R	R	R	R	R	R	R	R	S	64	8	64	64	+	–	–	ISPpu21	1
R	R	R	R	R	R	R	R	R	64	16	8	4	+	+	–	4 n Deletion	1
R	R	R	R	R	R	R	R	R	64	16	8	4	+	–	–	7n Deletion	1
R	R	R	R	R	R	R	R	R	64	16	8	8	+	+	–	Negative^**	1
R	R	R	R	R	R	R	R	S	64	16	16	16	+	–	–	ISPpu22	1
R	R	R	R	R	R	R	R	S	64	16	16	16	+	+	–	89n Deletion	1
R	R	R	R	R	R	R	R	R	64	16	32	16	+	–	–	4n Deletion	1
R	R	R	R	R	R	R	R	R	64	16	32	32	+	–	–	14n Deletion	1
R	R	R	R	R	R	R	R	S	64	16	32	32	+	+	–	3n Deletion	1
R	R	R	R	R	R	R	R	S	64	16	32	32	+	+	–	4n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	32	16	–	+	–	13n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	32	32	–	–	–	ISPpu21	1
R	R	R	R	R	R	R	R	R	64	32	32	32	–	–	–	5n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	32	32	–	–	–	6n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	32	32	–	+	–	4n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	64	32	–	–	–	22n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	64	64	–	–	–	4n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	64	64	–	+	–	62n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	64	64	–	+	–	Stop codon	1
R	R	R	R	R	R	R	R	R	64	32	64	64	–	+	–	5n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	64	64	–	+	–	7n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	64	64	–	+	–	20n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	64	64	–	+	–	31n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	128	128	–	–	–	1n Deletion	1
R	R	R	R	R	R	R	R	R	64	32	128	128	–	+	–	17n Deletion	1
R	R	R	R	R	R	R	R	R	128	32	64	64	+	+	–	1n Deletion	3
R	R	R	R	R	R	R	R	R	128	32	64	64	+	+	–	3n Deletion	1
R	R	R	R	R	R	R	R	R	128	32	64	64	+	+	–	4n Deletion	1
R	R	R	R	R	R	R	R	R	128	64	64	64	–	+	–	1n Deletion	1
R	R	R	R	R	R	R	R	R	256	256	64	64	–	+	–	13n Deletion	1
R	R	R	R	R	R	R	R	R	512	256	64	64	–	+	–	19n Deletion	1

¥

IMI; Imipenem, MEM; Meropenem, COL; Cloxacillin, ATM; Aztreonam, CB; Carbenicillin, AK; Amikacin, GM; Gentamicin, CIP; Ciprofloxacin, CPM; Cefepime, CAZ; Ceftazidime, n; nucleotides.

#

R, resistant; S, susceptible.

*

MIC; Minimum inhibitory concentration.

**

oprD in this isolate was not detectable by PCR.

Table 2

Distribution of susceptibility patterns, level of MICs to IMI and MEM, AmpC overproducer and carbapenemase genes (bla_VIM and bla_IMP) in 53 P. aeruginosa isolates resistant to carbapenem with oprD mutation.

Type of mutation		Number of isolates	Decrease in oprD expression
Frameshift	1-bp deletion	5	4
	Deletion of 2–98 bp	31	26
	ISPpu21 insertion	14	Not determined
	ISPpu22 insertion	1	Not determined
Premature stop codon	Single mutation	1	Normal
Non detectable by PCR	Unknown, large change	1	Not determination

Deletion of 1–98 bp (nt 81–179).

ISPpu21: 1194-bp IS(ISPpu21) at nt 603, encodes a 326-aa putative type transposase.

ISPpu22: 1232-bp IS(ISPpu22) at nt 81, encodes a 293-aa putative type transposase.

Table 3

Distribution of mutation and expression in the oprD gene in P. aeruginosa isolates resistant to carbapenems.

4. Discussion

Several mechanisms such as carbapenemase production, oprD mutation, AmpC and efflux pumps overexpression are involved in carbapenems resistance among P. aeruginosa strains [2,3]. Although, all isolates in this study were carbapenem resistant and MDR, nevertheless 13 (24%) isolates were susceptible to ceftazidime, indicating the importance of antimicrobial susceptibility testing in choosing of antibiotics for treatment of infections. In the present study, similar to several studies in Iran, bla_VIM and bla_IMP have been only carbapenemase genes that were identified in carbapenem-resistant isolates of P. aeruginosa [3,16,17]. Also, our study, was not in agreement with Hakemi Vala et al. and Bagheri Bejestani studies in Tehran, Iran, that reported no bla_VIM positive P. aeruginosa isolates from different clinical samples such as burns’ patients [18,19]. However, bla_VIM rates vary greatly among different studies [16–19] which may reflect differences in infection control policies and other factors.

In our study, MIC to of imipenem in bla_IMP and bla_VIM positive isolates was ≥ 32 µg/ml but the MIC to imipenem was ≤ 16 µg/ml in bla_IMP and bla_VIM negative isolates. This finding, suggests that carbapenemase genes increase the resistance to carbapenems in bla_IMP and bla_VIM positive isolates compared to bla_IMP and bla_VIM negative isolates (Table 2).

AmpC overproducer and mutational inactivation of oprD are known to be the main mechanisms of carbapenem resistance especially to imipenem in the absence of acquired carbapenemases [2].

AmpC overproducer, usually when is combined with efflux systems over-expression and/or down-regulation oprD, has been proven to lead to carbapenem resistance or increase of 2–4 folds MIC to carbapenems [2,20,21]. As it is shown in table 2, AmpC overproducer was correlated with increase of resistance to imipenem and because of the 18 (64.2%) AmpC overproducer isolates, the MIC of imipenem (MICs: 16–512 µg/ml) was 2–4-folds higher than of meropenem (MICs: 4–128 µg/ml) (P < 0.0001).

In this study similar to other reports from Korea and Spain and other countries, oprD gene was defected by deletion mutation in 71.7% of isolates [10,21,22]. In our study, all mutation in oprD were occurred in the parts of the gene that were encoding loop 2 and 3 in OprD protein. The OprD porin has 8 loop structures on the external surface of outer membrane in P. aeruginosa [1]. Loop 2 and loop 3 on external surface have important roles in the entrance of carbapenems especially imipenem [1]. Therefore, mutations (substitution or deletion) within loop 2 and loop 3 have a potential to show an imipenem resistance phenotype [1].

In our study, oprD was disrupted by two IS elements including ISPpu22 and ISPpu21. ISPpu22 is a novel insertion sequence in the oprD porin gene of a carbapenem-resistant P. aeruginosa and it was reported, for the first time, from Iran [23]. ISPpu21 was previously reported in Pseudomonas putida and possibly has been transferred from P. putida to P. aeruginosa. Also ISPpu21 was previously reported in P. aeruginosa by Estepa et al. in GenBank (GenBank accession number: JX440360).

In this study, transcriptional levels of oprD were decreased in 56.6% of imipenem and meropenem resistant isolates. Similar to our study, down regulation of oprD gene in carbapenem resistant P. aeruginosa isolates has been reported by several studies. Several studies in 2009 and 2012, have reported that down regulation of oprD was responsible for reduced susceptibility to imipenem among carbapenem resistant P. aeruginosa [10,13,24].

Finally, our results showed that OprD defective and AmpC overproducer are two important mechanisms that involved in carbapenem-resistant among P. aeruginosa isolated from burn patients in Tehran, Iran.

5. Conclusions

Although the production of carbapenemases is the common mechanism of resistance to carbapenems in P. aeruginosa but resistance to carbapenems can also be driven by oprD mutation and AmpC in P. aeruginosa isolated from burn patients, in Tehran, Iran.

Conflict of interests

There is no conflict of interests between authors for this work.

Acknowledgments

This research has been supported by Tehran University of Medical Sciences & Health Services grant 93-02-30-25762.

Footnotes

Peer review under responsibility of Ministry of Health, Saudi Arabia.

Reference

[1].H Li, YF Luo, BJ Williamsb, TS Blackwell, and CM Xie, Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies, Int J Med Microbiol, Vol. 302, 2012, pp. 63-8.

[2]PD Lister, DJ Wolter, and ND Hanson, Antibacterial-resistant pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms, Clin Microbiol Rev, Vol. 22, No. 4, 2010, pp. 582-610.

[3]DK Neyestanaki, A Mirsalehian, F Rezagholizadeh, F Jabalameli, M Taherikalani, and M Emaneini, Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients, Burns, Vol. 40, No. 8, 2014, pp. 1556-61.

[4]B Libisch, B Balogh, and M Fuzi, Identification of Two Multidrug-Resistant Pseudomonas aeruginosa Clonal Lineages with a Countrywide Distribution in Hungary, Curr Microbiol, Vol. 58, No. 2, 2009, pp. 111-6.

[5]D Kalantar-Neyestanaki, F Jabalameli, A Mirsalehian, and M Emaneini, Evaluation of “β-lactamase disk test method” for detection of Extended-Spectrum-β-lactamases in clinical isolates of Pseudomonas aeruginosa with multidrug resistance, J Kerman Univ Med Sci, Vol. 23, No. 1, 2016, pp. 1-11.

[6]A Mirsalehian, D Kalantar-Neyestanaki, K Nourijelyani, K Asadollahi, M Taherikalani, M Emaneini, and F Jabalameli, Detection of AmpC-β-lactamases producing isolates among carbapenem resistant P. aeruginosa isolated from burn patient. Iran, J Microbiol, Vol. 6, No. 5, 2014, pp. 306-10.

[7]E Willemsa, J Verhaegena, J Magermanb, S Nysb, and R Cartuyvelsb, Towards a phenotypic screening strategy for emerging β-lactamases in Gram-negative bacilli, Int J Antimicrob Agents, Vol. 41, 2013, pp. 99-109.

[8]CR Mahon, DC Lehman, and G Manuselis, Text book of diagnostic microbiology, Fourth edition, 2007, pp. 564-86.

[9]Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing, 24nd Informational Supplement, M100–S24, Clinical and Laboratory Standards Institute, Wayen, P.A., 2014.

[10]JM Rodríguez-Martínez, L Poirel, and P Nordmann, Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa, Antimicrob Agents Chemother, Vol. 53, No. 11, 2009, pp. 4783-8.

[11]L Poirel, TR Walsh, V Cuvillier, and P Nordmann, Multiplex PCR for detection of acquired carbapenemase genes, Diagn Microbiol Infect Dis, Vol. 70, No. 1, 2011, pp. 119-23.

[12]F Fallah, R Shams Borhan, and A Hashemi, Detection of bla(IMP) and bla(VIM) metallo-β lactamases genes among Pseudomonas aeruginosa strains, Int J Burn Trauma, Vol. 3, No. 2, 2013, pp. 122-4.

[13]DE Xavier, RC Picão, R Girardello, LC Fehlberg, and AC Gales, Efflux pumps expression and its association with porin down-regulation and β-lactamase production among Pseudomonas aeruginosa causing bloodstream infections in Brazil, BMC Microbiol, Vol. 10, No. 217, 2010, pp. 1-7.

[14]DJ Wolter, AJ Schmidtke, ND Hanson, and PD Lister, Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin, Antimicrob Agents Chemother, Vol. 51, No. 8, 2007, pp. 2997-3000.

[15]G Cabot, AA Ocampo-Sosa, MA Domínguez, JF Gago, C Juan, F Tubau, et al., Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones, Antimicrob Agents Chemother, Vol. 56, No. 12, 2012, pp. 6349-57.

[16]MA Bahar, S Jamali, and A Samadikuchaksaraei, Imipenem resistant Pseudomonas aeruginosa strains carry metallo-betalactamase gene bla(VIM) in a level I Iranian burn hospital, Burns, Vol. 36, No. 6, 2010, pp. 826-30.

[17]AD Khosravi and F Mihani, Detection of metallo-betalactamase-producing Pseudomonas aeruginosa strains isolated from burn patients in Ahwaz, Iran, Diagn Microbiol Infect Dis, Vol. 60, No. 1, 2008, pp. 125-8.

[18]M Hakemi Vala, M Hallajzadeh, A Hashemi, H Goudarzi, M Tarhani, M Sattarzadeh Tabrizi, et al., Detection of Ambler class A, B and D ß-lactamases among Pseudomonas aeruginosa and Acinetobacter baumannii clinical isolates from burn patients, Ann Burns Fire Disasters, Vol. 27, No. 1, 2014, pp. 8-13.

[19]F Bagheri Bejestani, M Hakemi-Vala, R Momtaheni, O Bagheri Bejestani, and M Gholami, The frequency of imp and vim genes Among pseudomonas aeruginosa isolates from Children’s medical center of tehran, Arch Clin Infect Dis, Vol. 10, No. 1, 2015, pp. e20991.

[20]K Poole, Pseudomonas aeruginosa: resistance to the max, Front Microbiol, Vol. 2, 2011, pp. 65.

[21]E Riera, G Cabot, X Mulet, M Garcıa-Castillo, RD Campo, C Juan, et al., Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem, J Antimicrob Chemother, Vol. 66, No. 9, 2011, pp. 2022-7.

[22]J Lee and KS Ko, OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from South Korea, Int J Antimicrob Agents, Vol. 40, No. 2, 2012, pp. 168-72.

[23]D Kalantar-Neyestanaki, M Emaneini, F Jabalameli, M Taherikalani, and A Mirsalehian, ISPpu22, a novel insertion sequence in the oprD porin gene of a carbapenem-resistant Pseudomonas aeruginosa isolate from a burn patient in Tehran, Iran, Iran J Microbiol, Vol. 7, No. 5, 2015, pp. 247-50.

[24]S Hammami, R Ghozzi, B Burghoffer, G Arlet, and S Redjeb, Mechanisms of carbapenem resistance in non-metallo-beta-lactamase producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospital, Pathol Biol, Vol. 57, No. 7–8, 2009, pp. 530-5.

<Previous Article In Issue

Download article (PDF)

Next Article In Issue>

Journal: Journal of Epidemiology and Global Health
Volume-Issue: 7 - 3
Pages: 155 - 159
Publication Date: 2017/04/29
ISSN (Online): 2210-6014
ISSN (Print): 2210-6006
DOI: 10.1016/j.jegh.2017.04.002 How to use a DOI?
Open Access: This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Cite this article

ris enw bib

TY  - JOUR
AU  - Akbar Mirsalehian
AU  - Davood Kalantar-Neyestanaki
AU  - Morovat Taherikalani
AU  - Fereshteh Jabalameli
AU  - Mohammad Emaneini
PY  - 2017
DA  - 2017/04/29
TI  - Determination of carbapenem resistance mechanism in clinical isolates of Pseudomonas aeruginosa isolated from burn patients, in Tehran, Iran
JO  - Journal of Epidemiology and Global Health
SP  - 155
EP  - 159
VL  - 7
IS  - 3
SN  - 2210-6014
UR  - https://doi.org/10.1016/j.jegh.2017.04.002
DO  - 10.1016/j.jegh.2017.04.002
ID  - Mirsalehian2017
ER  -

download .riscopy to clipboard